{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:15:00Z","timestamp":1780611300913,"version":"3.54.1"},"reference-count":59,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MSD China"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Chinese national guidelines recommend various systemic therapies for patients with advanced hepatocellular carcinoma (HCC), but optimal treatment selection remains uncertain. To summarize the evidence supporting the systemic treatment of Chinese patients with advanced HCC, we performed a systematic review using a literature search of PubMed, Embase, China National Knowledge Infrastructure, and the Chinese Scientific Journal Database between 1 January 2009 and 15 June 2021, and abstracts from ASCO 2020, ASCO GI 2021, ESMO 2020, and ESMO GI 2020. The inclusion criteria were: Chinese patients aged \u226518 years with advanced HCC; first- or second-line systemic therapy; an evaluation of the efficacy or safety outcomes; and a randomized controlled, non-randomized controlled, prospective, or retrospective design. Thirty reports were identified for the following therapies: the single-agent tyrosine kinase inhibitor (TKI; n = 10), single-agent programmed death-1 (PD-1) inhibitor (n = 4), chemotherapy (n = 5), PD-1\/programmed death-ligand 1 (PD-L1) inhibitor plus TKI (n = 6), PD-1\/PD-L1 inhibitor plus bevacizumab or biosimilar (n = 4), and PD-1\/PD-L1 inhibitor plus chemotherapy (n = 1). The heterogeneity between the studies precluded statistical analysis and the data were summarized using tables. In the first-line setting, evidence supported the use of atezolizumab or sintilimab plus bevacizumab or a biosimilar. There remains insufficient evidence to determine the optimal approved TKI-based therapeutic option, and active controlled trials in the second-line setting were lacking.<\/jats:p>","DOI":"10.3390\/curroncol29100575","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T01:52:21Z","timestamp":1665193941000},"page":"7305-7326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review"],"prefix":"10.3390","volume":"29","author":[{"given":"Lan","family":"Zhang","sequence":"first","affiliation":[{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Sun","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatic Surgery II, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Beijing 100032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijie","family":"Zhang","sequence":"additional","affiliation":[{"name":"MRL Global Medical Affairs, MSD China, Shanghai 200233, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Ren","sequence":"additional","affiliation":[{"name":"Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","first-page":"141","article-title":"Update in global trends and aetiology of hepatocellular carcinoma","volume":"22","author":"Rawla","year":"2018","journal-title":"Contemp. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.21147\/j.issn.1000-9604.2018.06.01","article-title":"Liver cancer incidence and mortality in China: Temporal trends and projections to 2030","volume":"30","author":"Zheng","year":"2018","journal-title":"Chin. J. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/EDBK_200939","article-title":"Global epidemiology, prevention, and management of hepatocellular carcinoma","volume":"38","author":"Mak","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: The bridge study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"452","DOI":"10.21037\/hbsn-20-480","article-title":"2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: Updates and insights","volume":"9","author":"Xie","year":"2020","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_10","unstructured":"National Comprehensive Cancer Network (NCCN) (2021). Clinical Practice Guidelines in Oncology, National Comprehensive Cancer Network (NCCN). Version 1."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1002\/cncr.30237","article-title":"Comparison of hepatocellular carcinoma in Eastern versus Western populations","volume":"122","author":"Choo","year":"2016","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clon.2019.06.002","article-title":"Contrasting some differences in managing advanced unresectable hepatocellular carcinoma between the east and the west","volume":"31","author":"Lee","year":"2019","journal-title":"Clin. Oncol."},{"key":"ref_13","unstructured":"(2020). Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition). Zhonghua Gan Zang Bing Za Zhi, 28, 112\u2013128."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_17","first-page":"S173","article-title":"Clinical efficacy and safety of Apatinib in first-line treatment for a hepatocellular carcinoma: A prospective study","volume":"13","author":"Zhang","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: A randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.3748\/wjg.v26.i30.4465","article-title":"Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China","volume":"26","author":"Wang","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1010428317695030","DOI":"10.1177\/1010428317695030","article-title":"Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data","volume":"39","author":"Ye","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.18632\/oncotarget.6781","article-title":"Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: Final outcome from the Chinese patient subset of the GIDEON study","volume":"7","author":"Ye","year":"2016","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2021.39.3_suppl.316","article-title":"The use of cabozantinib in advanced hepatocellular carcinoma (HCC): Hong Kong multi-center experience","volume":"39","author":"Dong","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e15682","DOI":"10.1200\/JCO.2017.35.15_suppl.e15682","article-title":"A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma","volume":"35","author":"Bi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105596","DOI":"10.18632\/oncotarget.22337","article-title":"Apatinib is effective for treatment of advanced hepatocellular carcinoma","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cncr.24029","article-title":"Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: Presence of lung metastasis predicts poor response","volume":"115","author":"Yau","year":"2009","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S689","DOI":"10.1016\/j.annonc.2020.08.1101","article-title":"985P A phase II study of camrelizumab for advanced hepatocellular carcinoma: Two-year outcomes and continued treatment beyond RECIST-defined progression","volume":"31","author":"Ren","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","article-title":"Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study","volume":"40","author":"Qin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2022.40.4_suppl.420","article-title":"Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208","volume":"40","author":"Edeline","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/sj.bjc.6605856","article-title":"A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients","volume":"103","author":"Yang","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s10330-011-0934-0","article-title":"Clinical study of FOLFOX4 regimen for patients of advanced hepatocellular carcinoma","volume":"11","author":"Zhu","year":"2012","journal-title":"Chin.-German J. Clin. Oncol."},{"key":"ref_33","first-page":"868","article-title":"Comparison of XELOX and FOLFOX4 regimens for treatment of advanced hepatocellular carcinoma","volume":"23","author":"Jiang","year":"2017","journal-title":"J. Chin. Oncol."},{"key":"ref_34","first-page":"70","article-title":"Clinical observation of advanced primary hepatocarcinoma with FOLFOX6 regimen","volume":"15","author":"Zhang","year":"2010","journal-title":"Chin. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S1305","DOI":"10.1016\/j.annonc.2020.10.191","article-title":"170P Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"31","author":"Chen","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with Apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.annonc.2020.04.211","article-title":"P-129 Camrelizumab combined with sorafenib versus sorafenib alone in patients with advanced hepatocellular carcinoma: A retrospective study","volume":"31","author":"Liu","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e16130","DOI":"10.1200\/JCO.2021.39.15_suppl.e16130","article-title":"Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma","volume":"39","author":"Lin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"684867","DOI":"10.3389\/fonc.2021.684867","article-title":"Clinical activity and safety of penpulimab (Anti-PD-1) with anlotinib as first-line therapy for unresectable hepatocellular carcinoma: An open-label, multicenter, phase Ib\/II trial (AK105-203)","volume":"11","author":"Han","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_41","first-page":"326","article-title":"Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study","volume":"29","author":"Yuan","year":"2021","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000513486","article-title":"Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: Phase 3 randomized, open-label imbrave150 study","volume":"10","author":"Qin","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S692","DOI":"10.1016\/j.annonc.2020.08.1107","article-title":"991P Sintilimab plus IBI305 as first-line treatment for advanced hepatocellular carcinoma","volume":"31","author":"Jia","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1200\/JCO.2020.38.15_suppl.3079","article-title":"Preliminary results of sintilimab plus different dose of IBI305 (anti-VEGF monoclonal antibody) in patients with advanced hepatocellular carcinoma: A phase Ib study","volume":"38","author":"Zhang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2147\/DDDT.S304857","article-title":"Camrelizumab combined with FOLFOX4 regimen as first-line therapy for advanced hepatocellular carcinomas: A sub-cohort of a multicenter phase Ib\/II study","volume":"15","author":"Li","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000515553","article-title":"Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.jceh.2014.05.004","article-title":"Treatment algorithms for managing hepatocellular carcinoma","volume":"4","author":"Saraswat","year":"2014","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.5604\/16652681.1184233","article-title":"Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm","volume":"15","author":"Richani","year":"2016","journal-title":"Ann. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.20.02672","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline","volume":"38","author":"Gordan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/575\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:55Z","timestamp":1760143495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["curroncol29100575"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29100575","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}